Lifestyle changes study for low-risk MDS blood disorder
Part of Blood & lymphatic clinical trials.
This trial tests whether a structured lifestyle program can help people with low-risk myelodysplastic syndromes (MDS) manage their health better. It mainly targets adults who are not getting frequent blood transfusions and have low hemoglobin levels.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old
- You have an MDS (or MDS/MPN) diagnosis confirmed by blood test
- Your MDS risk is very low, low, or intermediate (not high/very high)
- Your hemoglobin is below 11 g/dL, and you have not needed frequent transfusions
- Your activity level is limited at most a little (ECOG 0–2), and BMI is 20 or higher
- You can follow the nutrition and movement plan and agree to the study in writing
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
This trial tests an investigational drug called DISC-0974 for people with myelofibrosis or certain types of MDS who have low red blood cell counts (anemia). The goal is to see if this treatment can help improve anemia and reduce the need for blood transfusions.
This study tests a new therapy called MNV-201 for people with low-risk myelodysplastic syndromes (MDS) who have anemia and need regular blood transfusions. The goal is to see if this treatment can help reduce or stop the need for transfusions.
This study carefully evaluates people with myelodysplastic syndromes (MDS) and closely related blood disorders using detailed medical, blood, and bone marrow testing. The goal is to better understand these conditions and how they progress, which may help guide future care.
This trial tests an investigational drug called roxadustat to see if it can help people with a certain type of low-risk MDS who need frequent red blood cell transfusions. It's for patients who haven't responded to other anemia treatments.
This study tests a new drug, momelotinib, for people with a low-risk form of myelodysplastic syndrome (MDS) who need red blood cell transfusions and have already tried one other treatment (like ESAs or luspatercept). The goal is to see if momelotinib can help reduce transfusion needs.
Hear when a new Myelodysplastic Syndromes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.